NicOx
Generic ultram pills no prescription S.A. (Euronext Paris: COX) announced that a new analysis of the data
from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for
naproxcinod was presented yesterday at the American Heart Association
Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in
hypertensive volunteers was designed to compare the 24-hour blood pressure
profiles of naproxcinod 750 mg bid and naproxen 500 mg bid. Naproxcinod is
NicOx’ lead investigational product and the first compound in the new
Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of
anti-inflammatory agents.
This new post hoc analysis was accepted by the American Heart
Association scientific panel and compared the mean 24-hour systolic blood
pressure (SBP) as measured by ABPM in the two groups (i.e. naproxcinod vs.
naproxen), at the end of the 2 weeks of active treatment. The mean 24-hour
SBP showed a difference of 2.4 mmHg (standard error 0.87 mmHg) in favor of
naproxcinod as compared to naproxen (p=0.007) after 2 weeks of treatment.
Interestingly, for the daytime measurements (the 8 hours following the
morning dose), the mean 8-hour SBP showed a difference of 4.4 mmHg
(standard error 0.98 mmHg) in favor of naproxcinod as compared to naproxen
(pBuy soma pills | Generic cialis pills no prescription | Generic diflucan pills no prescription